Junshi Biotech H Share Announcement
Junshi Biotech: Junshi Biotech voluntarily discloses an announcement regarding the approval for marketing of treprilizumab in Hong Kong, China
Junshi Biotech voluntarily disclosed an announcement regarding the approval for marketing of treprilizumab in Hong Kong, China
Junshi Biotech voluntarily discloses an announcement on approval of the marketing application for a new drug with angerisimab injection
Junshi Biotech: Junshi Biotech H Share Announcement
Junshi Biotech H Share Announcement
Junshi Biotech H Share Announcement
Junshi Biotech: Junshi Biotech\'s announcement on the signing of a license and cooperation agreement between its holding subsidiary and Jisheng Aoma
Junshi Biotech: Junshi Biotech H Share Announcement
Junshi Biotech: Junshi Biotech voluntarily discloses the announcement that JS125 has obtained an approval letter for drug clinical trials
Junshi Biotech voluntarily disclosed the announcement that JS125 obtained a notice of approval for drug clinical trials
Announcement of Junshi Biotech on the signing of licensing and cooperation agreements between its holding subsidiary and Jisheng Aoma
Junshi Biotech H Share Announcement
Junshi Biotech voluntarily disclosed the announcement that treprilizumab was approved for marketing by the European Commission
Junshi Biotech\'s announcement on plans for shareholders holding 5% or more of the shares to reduce their shareholding
Haitong Securities Co., Ltd.\'s 2024 semi-annual follow-up report on the continuous supervision of Shanghai Junshi Biomedical Technology Co., Ltd.
Junshi Biotech\'s announcement on the implementation results of share repurchase
Junshi Biotech H Share Announcement
Junshi Biotech Investor Relations Activity Record Form (2024 Semi-Annual Results Briefing)
Junshi Biotech Announces Progress of Share Repurchase Through Centralized Bidding
No Data
No Data